AI Analysis | Feedback

Here are 1-2 brief analogies for Coeptis Therapeutics:

• A clinical-stage Gilead Sciences focused on pioneering universal cancer cell therapies.
• An early-stage Allogene Therapeutics, developing 'off-the-shelf' cell therapies for cancer.

AI Analysis | Feedback

• CD38-GEAR-NK: An allogeneic natural killer (NK) cell therapy developed to target CD38-expressing cancers like multiple myeloma.
• SNAP-CAR T: A universal CAR T-cell platform designed to rapidly and reversibly target multiple tumor antigens.
• CD38-mAb (FLT-001): A novel humanized monoclonal antibody targeting CD38 for various hematologic malignancies.

AI Analysis | Feedback

Coeptis Therapeutics (symbol: COEP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. As of its latest financial reports, the company is primarily engaged in research and development and conducting clinical trials for its drug candidates.

Due to its current stage of development, Coeptis Therapeutics does not yet have major commercial customers or generate revenue from the sale of approved pharmaceutical products. The company's financial filings indicate that it has not generated any revenue from product sales since its inception.

In the biopharmaceutical industry, companies at Coeptis Therapeutics' stage are focused on the costly and time-consuming process of drug discovery, preclinical testing, and multiple phases of clinical trials to achieve regulatory approval. Therefore, its primary activities involve R&D, clinical development, and seeking financing, rather than commercial sales.

Should Coeptis Therapeutics successfully develop and gain regulatory approval for any of its drug candidates, its future major customers would typically fall into the following categories:

1. Healthcare Providers: This would include hospitals, cancer treatment centers, clinics, and individual oncologists who prescribe and administer specialized cancer therapies to patients.
2. Pharmacies and Specialty Pharmacies: These entities would be responsible for dispensing approved pharmaceutical products, especially specialized or high-cost therapies.
3. Distributors and Other Pharmaceutical Companies: Coeptis Therapeutics might enter into licensing agreements, distribution partnerships, or co-commercialization agreements with larger pharmaceutical companies to leverage their established sales, marketing, and distribution networks for broader market access.

AI Analysis | Feedback

null

AI Analysis | Feedback

David Mehalick, Chairman, President and Chief Executive Officer

Mr. Mehalick is a co-founder of Coeptis Therapeutics and serves as Chairman of the Board, President, and Chief Executive Officer. He possesses over 30 years of experience across diverse industries including life sciences, technology, financial services, military contracting, entertainment, and consumer products. Mr. Mehalick began his career in financial services, moving into investment banking in the early 2000s, holding positions at First Union Capital Markets, Gruntal and Co., and Ferris Baker Watts. He was a founding partner in American Defense Systems, a military contractor that became public on the AMEX stock exchange. He has assisted and managed several organizations towards successful investor monetization, resulting in billions of dollars in transactions and financings. Mr. Mehalick has also served as Managing Director at Steeltown Consulting Group, LLC, Chief Business Officer at Sparta Healthcare Acquisition Corp., and previously as CFO of Information Technology Procurement Sourcing, Inc., and co-founder of American Scientific Resources, Inc. and World Health Alternatives, Inc. Coeptis went public following a SPAC transaction in October of the previous year (prior to December 2023).

Brian Cogley, Chief Financial Officer

Mr. Cogley joined Coeptis Therapeutics as Chief Financial Officer in 2023. Prior to this role, he was a Senior Manager-Accounting Advisory at Cfgi LLC and served as Vice President-Finance & Accounting at NexTier Bank, NA from 2017 to 2022. Mr. Cogley earned his undergraduate and Masters Business Administration degrees from Duquesne University of The Holy Spirit.

Daniel Yerace, Director and Vice President, Operations

Mr. Yerace is a co-founder of Coeptis Therapeutics and holds the position of Director and Vice President of Operations. He has over 15 years of experience in the pharmaceutical industry, where he has been a key strategist in supply chain management, business development, portfolio management, and corporate strategy. He is also a founder of Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc. Previously, Mr. Yerace was the Senior Director-Global Supply Chain at Kadmon Pharmaceuticals LLC. He holds an undergraduate degree and an MBA from Waynesburg College.

Christine Sheehy, Vice President, Compliance and Corporate Secretary

Ms. Sheehy is a pharmaceutical business leader with more than 25 years of experience. Her expertise includes the global commercialization of drug products and involvement in the development of targeted therapeutics, including cell and gene therapies.

Colleen Delaney, Chief Scientific and Medical Officer

Dr. Delaney is recognized as one of the premier scientists in the field of utilizing human cord blood for creating cells. She is a founder of Nohla Therapeutics, Inc. and Deverra Therapeutics, Inc. Her current roles include Director at the American Society for Blood & Marrow Transplantation, Director at Vicapsys Life Sciences, Inc. since 2022, and Clinical Professor at the University of Washington.

AI Analysis | Feedback

The key risks for Coeptis Therapeutics (COEP) primarily revolve around its financial viability and the inherent challenges of biopharmaceutical development, compounded by operational complexities arising from its diversified strategy.

1. Financial and Regulatory Instability: Coeptis Therapeutics faces significant financial and regulatory hurdles, including the retraction of financial statements for several periods in 2023 and 2024 due to accounting errors related to the improper recording of note agreements. This has led to the risk of delisting from the Nasdaq Capital Market for failing to meet the minimum bid price requirement. The company also has short-term obligations that exceed its liquid assets, which could hinder its ability to fund ongoing clinical trials and scale up manufacturing without securing additional financing. Furthermore, Coeptis has a history of unprofitability, with negative earnings and significant cash burn, indicating a need for future capital raises.
2. Clinical Trial and Product Development Risks: As a biopharmaceutical company, Coeptis Therapeutics is subject to the substantial risks inherent in drug development. Its product candidates in development may fail to advance through clinical trials or may not receive approval from regulatory authorities such as the U.S. Food and Drug Administration (FDA). There are also considerable costs associated with ongoing asset development and the pursuit of new development pathways. The biotech industry broadly experiences significant supply chain issues, which could further impact Coeptis's ability to conduct trials and manufacture products effectively.
3. Operational Complexities of Dual-Track Model: Coeptis has adopted a dual-track business model, aiming to balance revenue generation through AI-powered technology and other commercial activities with its core therapeutic research. While intended to create resilience and reduce reliance on dilutive funding, this strategy introduces operational complexities and potential weaknesses in execution. Successfully managing and allocating resources between diverse commercial endeavors and demanding biotech research could pose a significant challenge.

AI Analysis | Feedback

The accelerated development and potential market launch by more advanced competitors of superior or more cost-effective allogeneic CAR T-cell therapies could significantly diminish the future market potential for Coeptis's own preclinical allogeneic cell therapy pipeline.

Furthermore, the rapid emergence and increasing adoption of novel, highly effective targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs) for the indications currently treated by FYARRO (breast cancer, NSCLC, pancreatic cancer) pose an emerging threat by potentially displacing older chemotherapy agents like paclitaxel and eroding FYARRO's revenue base.

AI Analysis | Feedback

Coeptis Therapeutics (COEP) is developing cell therapy platforms for various diseases, primarily focusing on cancer. The addressable markets for its main products and platforms can be broadly categorized within the global CAR T-cell therapy and allogeneic cell therapy markets, with a significant focus on multiple myeloma.

• Global CAR T-Cell Therapy Market: The global CAR T-cell therapy market was valued at approximately USD 4.38 billion in 2023 and is projected to grow to USD 16.35 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032. Another estimate places the market at USD 4.65 billion in 2024, expected to reach USD 15.97 billion by 2030, with a CAGR of 22.2% from 2025 to 2030. North America held the largest share of this market, accounting for 68.72% in 2023.
• CAR T-Cell Therapy for Multiple Myeloma Market: Coeptis's CD38-GEAR-NK, COEP-003, and the GEAR Cell Therapy Platform are relevant to multiple myeloma. The global CAR T-cell therapy market specifically for multiple myeloma was valued at approximately USD 2.5 billion in 2023 and is projected to reach USD 12 billion by 2032, with a CAGR of 19.4%. The United States is the largest market for CAR T-cell therapy for multiple myeloma. Next-generation multiple myeloma therapies, which include CAR T-cell therapies, are expected to collectively rise from USD 1.9 billion in 2024 to USD 9.5 billion by 2033 globally. In the U.S., this market was USD 10.4 billion in 2024 and is expected to exceed USD 17 billion by 2033.
• Global Allogeneic Cell Therapy Market: Coeptis's allogeneic cellular immunotherapy platform and GEAR Cell Therapy Platform are part of this market. The global allogeneic cell therapy market is estimated to be worth USD 1.55 billion in 2025 and is anticipated to grow at a CAGR of 5.9% during the forecast period. Other reports estimate the global allogeneic cell therapy market size at USD 2.64 billion in 2025, reaching USD 6.79 billion by 2032 at a CAGR of 14.42%. North America held the largest market share, with over 80% in 2022 and 2024. Hematological disorders, which Coeptis targets, accounted for the largest share of the allogeneic cell therapy market, at 59.0% in 2024.
• CPT60621 for Parkinson's Disease: Market size for this specific product or its therapeutic area within cell therapy was not identified in the provided search results.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Coeptis Therapeutics (COEP)

• Expansion of NexGenAI Affiliates Network Platform: Coeptis Therapeutics anticipates rapid expansion of its NexGenAI Affiliates Network platform throughout 2025, following the recent securing of new clients and expected recurring monthly revenue from its AI-driven marketing solutions.
• Growth in Data Security Sector: The launch of Coeptis Technologies and the strategic acquisition of significant technology assets from a risk mitigation software company, which boasts over 10,000 customers globally, is expected to introduce well-established, revenue-generating assets within the booming data security market.
• Advancement of Cell Therapy Pipeline: The company continues to advance its biopharmaceutical pipeline, particularly the GEAR Cell Therapy Platform for cancer treatment, for which it secured exclusive worldwide rights, and the SNAP-CAR cell therapy platform for cancer and autoimmune diseases, with ongoing development and potential for clinical trials. Successful progression and eventual commercialization of these therapies are significant long-term revenue drivers.
• Strategic Partnerships and Collaborations in Technology and Biopharma: Coeptis is actively engaging in strategic partnerships to enhance its market position and diversify offerings. Examples include collaborations with NUBURU for AI and robotics in the defense sector and with MarketLeverage for AI-powered affiliate marketing, which are expected to drive innovation and client acquisition.
• New Technology Division and Venture Investments: The formation of Coeptis Technologies and the launch of the COEP Venture Group to invest in AI, Robotic Process Automation (RPA), and AI agent startups demonstrate a strategic shift towards generating revenue through broader technological innovation and targeted investments in high-growth areas.

AI Analysis | Feedback

Share Issuance

• Coeptis Therapeutics completed a $10 million Series A preferred stock offering in February 2025.
• The company followed this with a private placement targeting between $2.5 million and $5 million in July 2025.
• On June 15, 2023, Coeptis Therapeutics issued 23,691,036 shares, raising $2.15 million.

Inbound Investments

• Coeptis Therapeutics secured $10 million through a Series A preferred stock offering in February 2025.
• The company raised additional capital via a private placement targeting $2.5 million to $5 million in July 2025.
• Coeptis Therapeutics' cash position improved significantly from $532,885 at year-end 2024 to $1,996,726 by June 30, 2025, partly due to these capital raises.

Outbound Investments

• In February 2025, Coeptis Therapeutics launched COEP Venture Group, an investment arm focused on funding and accelerating technology startups in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents.
• Coeptis Therapeutics acquired 50% ownership interests in CD38-Diagnostic in December 2021 and the CD38-GEAR-NK product candidate in November 2022, following the exercise of options in August 2021.
• In April 2025, Coeptis Therapeutics entered into a definitive merger agreement with Z Squared Inc., a Dogecoin mining company, which will result in Z Squared becoming a wholly-owned subsidiary in exchange for 9,000 U.S.-based Dogecoin mining machines.